Biotech Values

[flatlander_60048]

Any thoughts about BCRX

NVS' recent failure to win approval for its gout drug prompted me to take a look at Biocryst. They have a gout drug in Phase II and the US Gov recently ponied up money for their phase III clinical trial for peramivir (flu treatment). The following bloomberg article peaked my interest.

My opinion is that BCRX is likely to be dead money until either swine flu re-emerges or theit is news on the trial or partnering of one of their candidates. I fully expect that the results of the Phase 3 Peramivir trial will be positive since there is adequate evidence from the 2009 emergency use authorization to draw inferences about the treatment effectiveness. Furthermore, peramivir has been approved in Asia.

The cash situation looks tenuous, but they appear to be looking to partner their gout drug.

FL

http://www.bloomberg.com/news/2011-06-09/swine-flu-variation-emerges-with-power-to-resist-drugs-researchers-say.html?cmpid=yhoo